Table 2.
Participant Characteristics Used in the Immunologic Analysis
| First‐Time Vaccination | Booster Vaccination | Maintain | |||||
|---|---|---|---|---|---|---|---|
| Failure | Responder | Total (2016) | 2015 | 2016 | Total | Total (2016) | |
| Vaccine | Heptavax‐II | Heptavax‐II | Bimmugen | Heptavax‐II | ‐ | ||
| Number | 11 | 36 | 47 | 30 | 32 | 62 | 20 |
| Male | 9 | 16 | 25 | 15 | 16 | 31 | 9 |
| Female | 2 | 20 | 22 | 15 | 16 | 31 | 11 |
| Age (mean ± SD), years | 21.9 ± 1.21 | 21.8 ± 1.15 | 21.8 ± 1.16 | 35.8 ± 9.87 | 30.2 ± 8.86 | 32.8 ± 9.65 | 38.2 ± 8.14 |
| Health check data | |||||||
| Height (cm) | 170.2 | 163.6 | 165.18 | 164.1 | 165.6 | 164.8 | 165.2 |
| Weight (kg) | 62.0 | 57.7 | 58.7 | 54.6 | 60.7 | 58 | 60.7 |
| BMI (kg/m2) | 21.3 | 21.4 | 21.8 | 20.3 | 22.0 | 21.3 | 22.1 |
| WBC (/μL) | NA | NA | NA | 6.8 | 6.4 | 6.5 | 6.4 |
| RBC (/μL) | NA | NA | NA | 450.5 | 471.9 | 464.7 | 458.3 |
| Hb (g/dL) | NA | NA | NA | 13.4 | 14.2 | 13.8 | 13.8 |
| Ht (mg/dL) | NA | NA | NA | 41.6 | 43.8 | 43.1 | 43.1 |
| Plt (/μL) | NA | NA | NA | 27.4 | 28.1 | 27.8 | 27.9 |
| Neutro (%) | NA | NA | NA | 57.7 | 55.0 | 56.1 | 61.6 |
| Ly (%) | NA | NA | NA | 31.7 | 35.6 | 34 | 29.1 |
| AST (IU/L) | 22.3 | 21.4 | 21.6 | 21.8 | 24.4 | 23.6 | 24.2 |
| ALT (IU/L) | 19.4 | 18.9 | 19 | 15.4 | 22.1 | 20.3 | 23.6 |
| γGT (IU/L) | 25.5 | 25.1 | 25.2 | 24.0 | 21.6 | 22.7 | 24.8 |
| Alb (g/dL) | 4.6 | 4.7 | 4.69 | 4.6 | 4.5 | 4.57 | 4.58 |
| T‐chol (mg/dL) | 176.6 | 186.4 | 184.1 | 184.1 | 187.1 | 187.5 | 198.2 |
| TG (mg/dL) | 118.5 | 87.9 | 95.1 | 74.3 | 79.3 | 79.4 | 83.6 |
Abbreviations: Alb, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; γGT, gamma‐glutamyltransferase; Hb, hemoglobin; Ht, hematocrit; Ly, lymphocytes; Neutro, neutrophils; Plt, platelets; RBC, red blood cell count; T‐chol, total cholesterol; TG, triglyceride; WBC, white blood cell count.